Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Articles published by EQRx

EQRx and CM Life Sciences III Announce Effectiveness of Form S-4 Registration Statement and Stockholder Meeting Details to Vote on Proposed Business Combination
From EQRx
Via Business Wire
EQRx to Present at the 4th Annual Evercore ISI HealthCONx Conference
From EQRx
Via Business Wire
EQRx Announces Partnership Agreement with Abdul Latif Jameel Health to Commercialize Lead Oncology Programs in Middle East, Turkey and Africa
From EQRx
Via Business Wire
EQRx and Evotec Announce Integrated Drug Discovery and Development Partnership
From EQRx
Via Business Wire
Tickers EVO
EQRx Launches “Remaking Medicine: On The Record” Investor Video Series
From EQRx
Via Business Wire
EQRx and NHSE Sign Memorandum of Understanding to Enter into England’s First Population Health Partnership for Cancer Drugs
From EQRx
Via Business Wire
EQRx Appoints Kathy Giusti to Board of Directors
From EQRx
Via Business Wire
EQRx Announces Presentation of Phase 3 Data Demonstrating a Progression-Free Survival Benefit with Sugemalimab Consolidation Therapy in Patients with Stage III NSCLC at ESMO Congress 2021
From EQRx
Via Business Wire
EQRx Announces Presentation of Updated Data from Pivotal Phase 3 Study of Anti-PD-L1 Antibody Sugemalimab in Combination with Chemotherapy as a First-Line Treatment for Stage IV NSCLC
From EQRx
Via Business Wire
EQRx to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
From EQRx
Via Business Wire
EQRx Appoints Richard Buckley as Chief Corporate Affairs Officer
From EQRx
Via Business Wire
EQRx Announces Formation of Mission Advisory Board
From EQRx
Via Business Wire
EQRx Appoints Carlos Garcia-Echeverria, Ph.D., as Chief of Rx Creation
From EQRx
Via Business Wire
EQRx and Exscientia Enter Strategic Drug Creation, Development, and Commercialization Collaboration to Accelerate the Advancement of New World-Class Medicines
From EQRx
Via Business Wire
Primary Endpoint Met in Phase 3 Study of the Anti-PD-L1 Antibody Sugemalimab in Stage III Non-Small Cell Lung Cancer
From EQRx
Via Business Wire
Aumolertinib Significantly Prolongs Progression-Free Survival with Fewer Side Effects in the First-Line Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
From EQRx
Via Business Wire
EQRx Appoints Jami Rubin as Chief Financial Officer and Kent Rogers as Chief Customer Officer
From EQRx
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.